Table 1.
Demographics and Clinical Characteristics of Participants
| Characteristic | Participants (n = 95) |
|---|---|
| Median age at enrollment (IQR), y | 56 (49–64) |
| Age grouping | |
| <65 y | 74 (77.9) |
| ≥65 y | 21 (22.1) |
| Biological sex | |
| Male | 39 (41.1) |
| Female | 56 (58.9) |
| Race | |
| White | 46 (48.4) |
| Black or African American | 37 (38.9) |
| Asian | 5 (5.3) |
| American Indian or Alaska Native | 1 (1.1) |
| Native Hawaiian or other Pacific Islander | 1 (1.1) |
| Other | 5 (5.3) |
| Ethnicity | |
| Hispanic or Latinx | 13 (13.8) |
| Median BMI (IQR), kg/m2 | 29.3 (26.0–35.4) |
| BMI groupa | |
| Normal (<25 kg/m2) | 19 (20.0) |
| Overweight or obese (≥25 kg/m2) | 74 (77.9) |
| Smoking status | |
| Never smoker | 68 (71.6) |
| Ever smoker | 4 (4.2) |
| Missing | 23 (24.2) |
| Hypertension | 39 (41.1) |
| Cardiovascular disease other than hypertension | 15 (15.8) |
| COPD or asthma | 16 (16.8) |
| Chronic kidney disease | 3 (3.2) |
| Diabetes | 15 (15.8) |
| Cancer not in remission | 4 (4.3) |
| Immunocompromisedb | 9 (9.5) |
| Fever as 1 of first 3 COVID-19 symptoms | |
| Yes | 30 (31.6) |
| No | 60 (63.2) |
| Missing | 5 (5.3) |
| Cycle threshold value of first RT-PCRc | |
| Median (IQR) | 18.6 (15.0–23.7) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: IQR, interquartile range; BMI, body mass index; COPD, chronic obstructive pulmonary disease; RT-PCR, reverse transcription polymerase chain reaction.
aTwo participants had missing BMI information.
bImmunocompromised refers to participants who are solid organ or bone marrow transplant recipients, who have primary immunodeficiency or AIDS, or who were taking immune-modulating medications within 3 months of COVID-19 diagnosis such as chemotherapy, including biologics, mycophenolate mofetil, methotrexate, tumor necrosis factor inhibitors, or prednisone ≥20 mg/d.
cThe first SARS-CoV-2 RT-PCR was performed in the clinical laboratory before enrollment. Included here are cycle threshold values from the 59 participants whose first RT-PCR was run on the NeuMoDx platform within 7 days of symptom onset.